N-Acetylcysteine for Trichotillomania
SSRIs have a genuinely disappointing track record in trichotillomania — N-acetylcysteine offers a distinct glutamate-based mechanism with real but mixed trial support, not a settled answer.
K.D., a 19-year-old woman, is in her first year at a state college, living in a dormitory for the first time away from her family; she has taken to wearing her hair in a specific styled part that she has become skilled at using to conceal thinning at her crown. She has mild seasonal allergies and no other significant medical history.
She has pulled hair from her scalp since age twelve, worsening noticeably during stressful periods, and the transition to college — new roommates, a heavier course load, and the loss of her usual private space to pull without being seen — has brought it back to a level she describes as "worse than it's ever been." She trialed sertraline 150 mg for four months last year under her pediatrician's care with no noticeable change in pulling frequency, and has never engaged in formal habit reversal training. Her MGH-HPS today is 19, and a visible patch of thinning is present at her crown that she actively works to style around.
Trichotillomania sits in the same DSM-5 chapter as OCD, but SSRIs have a genuinely disappointing evidence record here specifically, with controlled trials showing effect sizes not meaningfully different from placebo in most studies — her own four-month trial with no response is consistent with that literature, not an unusual outcome. N-acetylcysteine, an amino acid that modulates glutamate signaling through the cystine-glutamate antiporter rather than acting on serotonin at all, showed a genuinely positive result in an early, well-designed adult trial, but subsequent work has been more mixed — a later randomized trial in children and adolescents, smaller than the original, found no separation from placebo. It carries a favorable safety profile and is available without a prescription in most jurisdictions, which makes it a reasonable option to discuss honestly — not because the evidence is strong, but because the risk of trying it is genuinely low relative to what's actually known.
A different mechanism, honestly framed evidence
Her SSRI trial failing isn't a surprising result — it matches what the trichotillomania literature actually shows for that class. N-acetylcysteine works through an entirely different mechanism, glutamate modulation via the cystine-glutamate antiporter rather than serotonin, so a prior SSRI failure doesn't predict anything about whether NAC would work for her. I'd be honest that the trial evidence is mixed, not strong, but the safety profile is favorable enough that a trial is reasonable.
I'd frame NAC as one option alongside habit reversal training, not instead of it — she's never actually had a real behavioral therapy trial, and HRT has more consistent evidence in trichotillomania specifically than either pharmacologic option we're discussing. I don't want a genuinely promising, evidence-supported behavioral treatment to get skipped because a supplement conversation is easier to have in one visit.
Practically, both can start now without conflicting with each other — NAC at a standard studied dose while she's referred for HRT, with a clear plan to reassess in twelve weeks rather than assume either one alone if she improves. If she does get better, we should be upfront in the chart that with two interventions started together, we won't be able to cleanly credit one over the other.
Agreed: N-acetylcysteine started today at a standard studied dose, referral placed for habit reversal training to begin in parallel rather than sequentially, and a combined-treatment reassessment scheduled at twelve weeks with an explicit chart note that improvement, if it occurs, cannot be cleanly attributed to either intervention alone.
No real disagreement among the three voices by the end — the discussion settled on running both evidence-supported options together rather than choosing one over the other.